AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

RECCE PHARMACEUTICALS LTD

0.360

-0.015-4.00%

Volume:130.69K

Turnover:47.25K

Market Cap:109.99M

PE:-3.18

High:0.375

Open:0.375

Low:0.355

Close:0.375

52wk High:0.730

52wk Low:0.347

Shares:305.52M

Float Shares:168.89M

Volume Ratio:1.31

T/O Rate:0.08%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.113

EPS(LYR):-0.090

ROE:-1277.62%

ROA:-581.01%

PB:-5.91

PE(LYR):-3.98

Loading ...

Overview Company News Filings

Recce Pharmaceuticals Gets Ethics Approval for New Study Arm in Phase 3 Trial of Diabetic Foot Infection Treatment

MT Newswires Live

Recce Pharmaceuticals in Position to Benefit from US ASPR Medical Countermeasures Strategy

MT Newswires Live

Recce Pharmaceuticals Ltd - Developing New Class of Synthetic Anti- Infectives Designed to Address Antibiotic-Resistant Superbugs

THOMSON REUTERS

Recce Pharmaceuticals Ltd-U.S. Government Releases Us$66.9b Amr Biodefense Strategy

THOMSON REUTERS

Recce Pharmaceuticals Reports Higher Cash Balance in June Quarter

MT Newswires Live

Recce Pharmaceuticals Extends Share Purchase Plan Closing Date

MT Newswires Live

Recce Pharmaceuticals Ltd-extension to Share Purchase Plan Closing Date

THOMSON REUTERS

ASX Preview: Australian Shares to Decline; Genesis Minerals to Acquire Vault Minerals for AU$5.274 per Share

MT Newswires Live

Recce Pharmaceuticals Secures Family 4 Patent for Anti-Infectives in Vietnam

MT Newswires Live

Recce Pharmaceuticals Ltd-vietnamese Patent Granted for Recce Anti-infectives

THOMSON REUTERS

Recce Pharmaceuticals Ltd-share Purchase Plan - Letter and Offer Booklet

THOMSON REUTERS

Australia's Recce Pharmaceuticals Slips to Near 11-month Low on Discounted Placement

Recce Pharmaceuticals to Raise AU$4 million via Share Placement; Shares Down 17%

MT Newswires Live

Recce Pharmaceuticals Raises A$4 Million Via Institutional Placement

Recce Pharmaceuticals - Raises A$4 Mln Via Institutional Placement at A$0.4 Per Share

THOMSON REUTERS

Recce Pharmaceuticals Requests Trading Halt Ahead of Equity Raise

MT Newswires Live

BRIEF-Recce Pharmaceuticals Requests Trading Halt Pending Announcement On Proposed Equity Capital Raise

Recce Pharmaceuticals Says HREC Approval Accelerates Global Phase 3 Dfi Strategy

Recce Says HREC Approval Progresses Phase 3 Clinical Trial of Diabetic Foot Infections Treatment Candidate

MT Newswires Live

Recce Pharmaceuticals Ltd - Hrec Approval Accelerates Global Phase 3 DFI Strategy

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/RCE.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RCE.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RCE.AU\",,,,,undefined,":{"symbol":"RCE.AU","market":"AU","secType":"STK","nameCN":"RECCE PHARMACEUTICALS LTD","latestPrice":0.36,"timestamp":1788243120000,"preClose":0.375,"halted":0,"volume":130690,"delay":0,"changeRate":-0.040000000000000036,"nameEN":"RECCE PHARMACEUTICALS LTD","floatShares":168893037,"shares":305520100,"eps":-0.113284,"marketStatus":"Not Yet Opened","change":-0.015,"latestTime":"09-01 16:12:00 AEST","open":0.375,"high":0.375,"low":0.355,"amount":47253,"amplitude":0.053333,"askPrice":0.38,"askSize":47012,"bidPrice":0.36,"bidSize":27233,"shortable":3,"etf":0,"ttmEps":-0.113284,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1788307200000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.375,"openAndCloseTimeList":[[1788220800000,1788242400000]],"volumeRatio":1.305177,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"RCE.AU","preClose":0.375,"auctionPrice":0.36,"auctionVolume":515,"auction":3,"marketStatus":"盘后竞价","timestamp":1788242963361}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RCE.AU\",,,,,undefined,":{"symbol":"RCE.AU","floatShares":168893037,"roa":"-581.01%","roe":"-1277.62%","lyrEps":-0.090423,"volumeRatio":1.305177,"shares":305520100,"dividePrice":0,"high":0.375,"amplitude":0.053333,"preClose":0.375,"low":0.355,"week52Low":0.347,"pbRate":"-5.91","psRate":"112.86","week52High":0.73,"institutionHeld":0,"latestPrice":0.36,"committee":-0.266402,"eps":-0.113284,"divideRate":0,"volume":130690,"delay":0,"ttmEps":-0.113284,"open":0.375,"prevYearClose":0.65,"prevWeekClose":0.367,"prevMonthClose":0.375,"prevQuarterClose":0.405,"fiveDayClose":0.375,"twentyDayClose":0.375,"sixtyDayClose":0.51,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RCE.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2025-04-15","symbol":"RCE.AU","defaultRemindTime":1744675200000,"type":"split","dateTimestamp":1744639200000,"forFactor":990476,"toFactor":1000000,"ratio":0.990476}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RCE.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RCE.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660419483","title":"Recce Pharmaceuticals Gets Ethics Approval for New Study Arm in Phase 3 Trial of Diabetic Foot Infection Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2660419483","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660419483?lang=en_us&edition=fundamental","pubTime":"2026-08-19 11:10","pubTimestamp":1787109038,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals  gained Human Research Ethics Committee approval for an amendment to its phase 3 clinical trial of Recce 327 topical gel for the potential treatment of diabetic foot infections in Australia, according to a Wednesday filing with the Australian bourse.The amendment adds a new randomized, active-controlled, non-inferiority study arm enrolling 208 participants, which will allow the company to generate comparative clinical data for the gel against antibiotic treatment options.The updated protocol also introduces wound imaging, which adds a further layer of objective assessment of the infection to strengthen the Recce 327 data package for global regulatory submissions, the company said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","RCE.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655984624","title":"Recce Pharmaceuticals in Position to Benefit from US ASPR Medical Countermeasures Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2655984624","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655984624?lang=en_us&edition=fundamental","pubTime":"2026-07-30 09:58","pubTimestamp":1785376729,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals  said it was well positioned to benefit from the US Administration for Strategic Preparedness and Response's  new five-year medical countermeasures funding strategy, which ranked antimicrobial resistance the second-highest funding priority in the plan, with $4.46 billion earmarked for broad-spectrum antimicrobials, according to a Thursday Australian bourse filing.The funding aims to help antimicrobial candidates through each development stage, from preclinical research through to clinical trials and regulatory approval.The firm's RECCE 327 treatment candidate has shown activity against a number of pathogen classes under its existing US Department of War programs, the filing noted.Its shares rose 1% in recent trading on Thursday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4009","BK7096","ASPR","RCE.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655479843","title":"Recce Pharmaceuticals Ltd - Developing New Class of Synthetic Anti- Infectives Designed to Address Antibiotic-Resistant Superbugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2655479843","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655479843?lang=en_us&edition=fundamental","pubTime":"2026-07-30 08:38","pubTimestamp":1785371927,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nTUE1ZTYHT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RCE.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655434758","title":"Recce Pharmaceuticals Ltd-U.S. Government Releases Us$66.9b Amr Biodefense Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2655434758","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655434758?lang=en_us&edition=fundamental","pubTime":"2026-07-30 08:38","pubTimestamp":1785371927,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nTUE1ZTYHT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RCE.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653223102","title":"Recce Pharmaceuticals Reports Higher Cash Balance in June Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2653223102","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653223102?lang=en_us&edition=fundamental","pubTime":"2026-07-21 12:03","pubTimestamp":1784606620,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals  ended the June quarter with a cash balance of AU$2.9 million, according to a Tuesday filing with the Australian bourse.The company closed the March quarter with a cash balance of AU$1.7 million, an earlier filing showed.During the June quarter, Recce saw net cash outflows from operating activities of AU$2.2 million, with research and development accounting for the majority of that spend.The company's shares gained 1% in recent Tuesday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","RCE.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652575266","title":"Recce Pharmaceuticals Extends Share Purchase Plan Closing Date","url":"https://stock-news.laohu8.com/highlight/detail?id=2652575266","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652575266?lang=en_us&edition=fundamental","pubTime":"2026-07-20 09:50","pubTimestamp":1784512217,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals  has extended the closing date of its share purchase plan  to Friday, providing eligible shareholders with additional time to subscribe for shares under the offer, according to a Monday Australian bourse filing.The SPP allows shareholders to acquire up to AU$30,000 worth of fully paid ordinary shares at AU$0.40 per share, with no brokerage or transaction fees applicable, the filing said.Participants will also have the opportunity to apply for free attaching options, subject to shareholder approval, which may include additional \"piggyback\" options upon exercise, the filing added.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","RCE.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652268917","title":"Recce Pharmaceuticals Ltd-extension to Share Purchase Plan Closing Date","url":"https://stock-news.laohu8.com/highlight/detail?id=2652268917","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652268917?lang=en_us&edition=fundamental","pubTime":"2026-07-20 07:29","pubTimestamp":1784503795,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260719:nTUE55RD6Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","RCE.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651398140","title":"ASX Preview: Australian Shares to Decline; Genesis Minerals to Acquire Vault Minerals for AU$5.274 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2651398140","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651398140?lang=en_us&edition=fundamental","pubTime":"2026-07-14 08:03","pubTimestamp":1783987435,"startTime":"0","endTime":"0","summary":"Australian shares are expected to open with a modest decline on Tuesday as oil surged over escalating Middle East tensions.Brent crude oil futures jumped over 9% to trade around $83 per barrel after U","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7104","RCE.AU","EIGA.AU","GIVE.AU","BEAR.AU","VAU.AU","E200.AU","BBOZ.AU","XAO.AU","GEAR.AU","DACE.AU","SLF.AU","GMD.AU","OZR.AU","ZYAU.AU","VAP.AU","BK4109","XKO.AU","VAS.AU","OZF.AU","IMLC.AU","IIGF.AU","STW.AU","QFN.AU","MTX","IISV.AU","QRE.AU","XJO.AU","BK7096","IOZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651147195","title":"Recce Pharmaceuticals Secures Family 4 Patent for Anti-Infectives in Vietnam","url":"https://stock-news.laohu8.com/highlight/detail?id=2651147195","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651147195?lang=en_us&edition=fundamental","pubTime":"2026-07-14 07:21","pubTimestamp":1783984898,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals  said the Intellectual Property Office of Vietnam formally granted a Family 4 patent for its anti-infectives, expiring in 2041, according to a Tuesday Australian bourse filing.The patent relates to the process for preparing the anti-infectives, as well as the use of its R327 and R529 therapy candidates, particularly in the treatment of bacterial infections and viral infections.It also relates to the administration of the anti-infectives by oral, inhalation, transdermal delivery, or by injection. They can also be delivered as an aerosol, gel, topical foam, or ointment.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RCE.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651147548","title":"Recce Pharmaceuticals Ltd-vietnamese Patent Granted for Recce Anti-infectives","url":"https://stock-news.laohu8.com/highlight/detail?id=2651147548","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651147548?lang=en_us&edition=fundamental","pubTime":"2026-07-14 06:56","pubTimestamp":1783983417,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nTUE4Y0XZN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RCE.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649488611","title":"Recce Pharmaceuticals Ltd-share Purchase Plan - Letter and Offer Booklet","url":"https://stock-news.laohu8.com/highlight/detail?id=2649488611","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649488611?lang=en_us&edition=fundamental","pubTime":"2026-07-06 07:06","pubTimestamp":1783292795,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260705:nTUE51YBQN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RCE.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646338649","title":"Australia's Recce Pharmaceuticals Slips to Near 11-month Low on Discounted Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2646338649","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646338649?lang=en_us&edition=fundamental","pubTime":"2026-06-26 10:27","pubTimestamp":1782440840,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Recce Pharmaceuticals slips to near 11-month low on discounted placement** Shares of Australia's Recce PharmaceuticalsRCE.AXfall as much as 19.6% to A$0.370, their lowest point since ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nL6N42Y05V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCE.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646380137","title":"Recce Pharmaceuticals to Raise AU$4 million via Share Placement; Shares Down 17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646380137","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646380137?lang=en_us&edition=fundamental","pubTime":"2026-06-26 09:44","pubTimestamp":1782438291,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals  received firm commitments to raise AU$4 million through the placement of 10 million new shares at AU$0.40 apiece, according to a Friday filing with the Australian bourse.The company is also launching a share purchase plan to allow eligible shareholders to subscribe for up to AU$30,000 worth of new shares to raise up to a further AU$4 million on the same terms as the placement, the filing said.Funds will be used to bolster the balance sheet for commercial licensing with a Middle Eastern pharmaceutical firm, and fund clinical trials and Investigational New Drug enabling activities, per the filing.Shares fell 17% in morning trade on Friday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","RCE.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646380832","title":"Recce Pharmaceuticals Raises A$4 Million Via Institutional Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2646380832","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646380832?lang=en_us&edition=fundamental","pubTime":"2026-06-26 09:27","pubTimestamp":1782437262,"startTime":"0","endTime":"0","summary":"BRIEF-Recce Pharmaceuticals Raises A$4 Million Via Institutional PlacementJune 26 (Reuters)-Recce Pharmaceuticals LtdRCE.AX:RAISES A$4 MILLION VIA INSTITUTIONAL PLACEMENT AT A$0.4 PER SHAREFurther company coverage:RCE.AX","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nFWN42X0R7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCE.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646382328","title":"Recce Pharmaceuticals - Raises A$4 Mln Via Institutional Placement at A$0.4 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2646382328","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646382328?lang=en_us&edition=fundamental","pubTime":"2026-06-26 08:03","pubTimestamp":1782432233,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nFWN42X0R7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","RCE.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645868025","title":"Recce Pharmaceuticals Requests Trading Halt Ahead of Equity Raise","url":"https://stock-news.laohu8.com/highlight/detail?id=2645868025","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645868025?lang=en_us&edition=fundamental","pubTime":"2026-06-24 09:16","pubTimestamp":1782263792,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals  requested an immediate trading halt on the Australian Securities Exchange pending an update on a proposed equity capital raising, according to a Wednesday Australian bourse filing.The company has requested that the halt remain in place until the earlier of Friday's normal trading session or release of the capital raising update, the filing added.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4588","BK4215","BK7096","RCE.AU","EQR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645850504","title":"BRIEF-Recce Pharmaceuticals Requests Trading Halt Pending Announcement On Proposed Equity Capital Raise","url":"https://stock-news.laohu8.com/highlight/detail?id=2645850504","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645850504?lang=en_us&edition=fundamental","pubTime":"2026-06-24 08:09","pubTimestamp":1782259765,"startTime":"0","endTime":"0","summary":"BRIEF-Recce Pharmaceuticals Requests Trading Halt Pending Announcement On Proposed Equity Capital RaiseJune 24  - Recce Pharmaceuticals Ltd RCE.AX:REQUESTS TRADING HALT PENDING ANNOUNCEMENT ON PROPOSED EQUITY CAPITAL RAISEFurther company coverage: RCE.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nFWN42V11B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","RCE.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645225012","title":"Recce Pharmaceuticals Says HREC Approval Accelerates Global Phase 3 Dfi Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2645225012","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645225012?lang=en_us&edition=fundamental","pubTime":"2026-06-22 09:34","pubTimestamp":1782092054,"startTime":"0","endTime":"0","summary":"June 22 (Reuters) - Recce Pharmaceuticals Ltd ::*HREC APPROVAL ACCELERATES GLOBAL PHASE 3 DFI STRATEGY*Further company coverage: RCE.AX* ((Reuters.Briefs@thomsonreuters.com;))  ((Reuters Investor Brie","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nRSD9Yrb1X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","RCE.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645201414","title":"Recce Says HREC Approval Progresses Phase 3 Clinical Trial of Diabetic Foot Infections Treatment Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2645201414","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645201414?lang=en_us&edition=fundamental","pubTime":"2026-06-22 08:53","pubTimestamp":1782089613,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals  said the Human Research Ethics Committee  approved a protocol amendment to its phase two clinical trial of Recce 327 topical gel treatment candidate for diabetic foot infections, advancing the study to a pivotal phase three clinical trial, according to a Monday Australian bourse filing.A pivotal phase three trial is considered a registrational study designed to generate the safety and efficacy data required to support regulatory approval applications. The trial has treated 18 of a potential 200 total patients and full enrollment is expected by the end of 2027.The protocol amendment expands eligibility to include moderate infection patients in addition to mild infection patients.The company said its completed phase two trial achieved a 93% primary efficacy endpoint at day 14 and 86% clinical response by day seven.Recce Pharmaceuticals' shares rose 1% in recent trading on Monday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","RCE.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645901127","title":"Recce Pharmaceuticals Ltd -  Hrec Approval Accelerates Global Phase 3 DFI Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2645901127","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645901127?lang=en_us&edition=fundamental","pubTime":"2026-06-22 08:03","pubTimestamp":1782086627,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nFWN42S06C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","RCE.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":32,"code":"91000000","status":"200"}]}}